Use of Cysteamine in the Treatment of Cystinosis

ConditionCystinosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-115
SponsorNational Human Genome Research Institute (NHGRI)

About this trial

Cystinosis is an inherited disease resulting in poor growth and kidney failure. There is no known cure for cystinosis, although kidney transplantation may help the renal failure and prolong survival. Both the kidney damage and growth failure are thought to be due to the accumulation of the amino acid cystine within the cells of the body. The cystine storage later damages other organs besides the kidneys, including the thyroid gland, pancreas, eyes, and muscle.

The drug cysteamine (Cystagon; ProCysBi) is an oral medication given to patients with cystinosis prior to kidney transplantation. The drug works by reducing the level of cystine in the white blood cells and muscle tissue. The drug may also decrease levels of cystine in the kidneys and other tissues.

This study has several goals:

1. Long-term surveillance of cysteamine treated patients. 2. Detection of new non-kidney complications of cystinosis. 3. Maintenance of a patient population for genetic testing (mutational analysis) of the cystinosis gene.\<TAB\>

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Patients with a diagnosis of cystinosis

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Cysteamine

    Drug

    Cystine-depleting agent

Treatment groups

330 Participants
are divided into 1 treatment group
Group A: Cystinosis1 intervention

Trial outcomes

Primary outcomes

1

Serve as a source of knowledge and advice for individual cystinosis patients and for the community at large

Serve as a source of knowledge and advice for individual cystinosis patients and for the community at large

Time frame
Follow-up can occur every two years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.